 Primary endpoint of 8-week transfusion independence met in the phase 3 IMerge study; Imetelstat was used as a monotherapy to treat patients with lower-risk myelodysplastic syndrome. Regulatory applications in the U.S. and Europe, of imetelstat for lower-risk myelodysplastic syndrome, are expected in 2023. 